Introduction
============

Hypercholesterolemia plays a key role in the development and progression of atherosclerosis and is a proven risk factor for coronary heart disease (CHD) ([@b57]; [@b52]; [@b53]; [@b10]). Therapeutic interventions aimed at lowering cholesterol levels both in primary and secondary prevention show a clear reduction in the incidence of CHD and stroke ([@b2]; [@b38]; [@b23]; [@b3]; [@b50]; [@b18]; [@b12]).

Although widely used in lipid lowering therapy, HMG CoA reductase inhibitors (even when administered at high doses) are frequently insufficient to achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals for many patients with hypercholesterolemia in everyday clinical practice ([@b27]). According to a recent study, a large proportion of high-risk hyperlipidemic patients receiving statins alone are not at goal even when physicians were free to use any statin and titrate according to their professional judgment ([@b22]). Over half (52%) of patients did not achieve LDL-C goal on the initial dose of statin, and 86% of these patients had still not reached goal after 6 months ([@b22]). Thus, a wide therapeutic gap exists between target LDL-C levels and what is achieved in clinical practice ([@b41]).

The therapeutic gap will undoubtedly increase in light of the recent amendments of the National Cholesterol Education Program Adult Treatment Program III (NCEP ATP III) guidelines, which recommend even more aggressive reductions in LDL-C levels for patients at high risk of CHD ([@b30]). The more aggressive cholesterol treatment goals proposed by the revised guidelines call for a more effective approach to maximize the cardiovascular benefits associated with lower LDL-C levels.

In the human body there are two major sources of cholesterol: first, the gastrointestinal tract where daily cholesterol is derived from the diet, bile input and desquamated cells ([@b37]); second, the liver which is the major source of cholesterol synthesis; in the human body ([@b29]). Approximately 50% of the cholesterol pool is absorbed and recirculated through the intestine, while the remainder is excreted through the feces ([@b34]; [@b56]). The intestinal pool is composed of both dietary, and the majority, from biliary excretion. A recent and more effective therapeutic strategy, is to treat both sources of cholesterol simultaneously with a complementary mechanism of action, by co-administering ezetimibe, a novel agent inhibiting cholesterol absorption, together with a statin, which inhibits cholesterol production in the liver ([@b34]; [@b37]; [@b56]). This results in dual inhibition of both sources of cholesterol provides significantly greater LDL-C reduction and subsequent goal attainment.

Ezetimibe can be effectively co-administered with any dose of any statin; indeed the benefits are consistent across the statin brand and dose subgroups and compared with single inhibition of cholesterol production, afforded by statins alone, provides consistently greater reductions in LDL-C through dual inhibition of both cholesterol production and absorption ([@b25]; [@b7]; [@b32]; [@b40];) The single product of ezetimibe/simvastatin provides superior LDL-C lowering efficacy with improved LDL-C goal attainment ([@b6]; [@b21]; [@b4]).

Here we summarize the pivotal role of both the liver and intestine in the overall balance of cholesterol in the body and describe the clinical impact and relevance of inhibiting both sources of cholesterol.

The liver and intestine: two sources of cholesterol
===================================================

The average adult body contains approximately 140 g of sterols, mainly in the form of cholesterol ([@b13]). This pool of cholesterol is derived from two major sources: synthesis of cholesterol by the liver (and extrahepatic sites) and absorption by the intestines ([@b29]; [@b37]). Approximately 500--1400 mg/day of cholesterol enters the body\'s cholesterol pool from synthesis (500--1000 mg) and diet (up to 500 mg/day) ([@b13]; [@b31]). However, the cholesterol pool usually changes little because cholesterol input is approximately balanced by cholesterol output via excretion in bile/feces, skin excretion, steroid hormone synthesis, etc ([@b13]; [@b31]).

The liver plays a central role in balancing cholesterol from all sources and also plays pivotal role in regulating plasma LDL-C levels ([@b17]). The hepatic pool of cholesterol is derived from local biosynthesis and from chylomicron remnants and lipoproteins. Cholesterol biosynthesis is regulated by the rate-limiting enzyme HMG CoA reductase, which catalyzes production of mevalonic acid from HMG CoA and represents the therapeutic target for statins. Cholesterol produced by liver is either secreted in bile or incorporated into lipoproteins (mainly VLDL) and secreted into plasma.

Intestinal cholesterol absorption represents another major route for the entry of cholesterol into the body, and, thus, this source can influence LDL-C concentration ([@b56]). Daily the cholesterol pool in the intestine comes from either dietary cholesterol (300--500 mg), from biliary excretion (800--1200 mg) and from desquamated cells (300 mg) ([@b34]; [@b56]). Of note, as a large part of the cholesterol absorbed results from the reabsorbtion of cholesterol excreted through the bile, it is appropriate to talk about entero-hepatic recirculation). The excess cholesterol is then excreted through the feces. Although the details of the molecular transport of cholesterol absorption are not fully understood, it is clear that cholesterol absorption in the intestine involves a complex triphasic process ([Figure 1](#fig1){ref-type="fig"}): intraluminal phase(digestion/hydrolysis of dietary lipids and micellar solubilization of cholesterol), membrane transport phase (cholesterol release from micelles at brush border membrane and uptake into enterocytes), and an intracellular phase (re-esterification, incorporation into nascent chylomicrons, and secretion into lymph) ([@b34]; [@b56]). Cholesterol appears to be specifically removed from the micelles as part of the absorption process: it is absorbed mainly in the duodenum and jejunum, but bile acids are not absorbed to an appreciable degree at these sites. Rather, specific bile acid transporters located in the ileum subsequently absorb bile acids, delivering them back to the liver and thus giving rise to an enterohepatic circulation ([@b37]). Until recently non-cholesterol sterols were not thought to be absorbed during this process; however, new insights into sitosterolemia or phytosterolemia, a rare autosomal recessive disorder caused by hyperabsorption and impaired biliary secretion of cholesterol and plant sterols, which subsequently accumulate in tissues causing tendon xanthoma and premature coronary artery disease, have depicted a different situation. The disease appears to be produced by mutations in two half-size ABC transporters, ABCG5 and ABCG8, localized at the apical membrane of the enterocyte and at the canalicular membrane in the liver. When functional, these transporters unite to form a full, active transporter and limit the absorption of both plant sterols and cholesterol by actively pumping them from enterocytes back into the intestinal lumen. These transporters may also promote the elimination of sterols in the liver by enhancing their excretion into bile. Mice lacking abcg5/abcg8 genes mimic the major phenotypes of human sitosterolemia(Salen et al 1992). A key protein involved in cholesterol absorption is NPC1L1, which has been found to be abundantly expressed in small intestine particularly in the jejunum at the brush-border membrane but also is present in subcellular compartments of human enterocyte, including lysosomes and mitochondria. *NPC1L1* was first described in 2000 ([@b15]); its name derives from the fact that it shares 42% amino acid identity with Niemann-Pick type C1 protein (NPC1), a protein involved in intracellular cholesterol transport and is also the causative gene for Niemann-Pick disease type C1 ([@b9]). In mouse, rat, and human, the small intestine showed a high level of *NPC1L1* mRNA expression ([@b1]) ([Figure 1](#fig1){ref-type="fig"}). With the exception of human liver, which showed similar levels of expression as the intestine, *NPC1L1* expression in all other tissues was \<10% of intestinal expression and was barely detectable in many tissues, in contrast with the fairly ubiquitous tissue expression of NPC1. Further analysis of the duodenal-ileal axis of rat small intestine demonstrated that peak expression of *Npc1L1* mRNA and NPC1L1 protein occurred in the proximal jejunum, which was also the predominant site for sterol absorption ([@b1]).
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The observation that mice lacking NPC1L1 have a markedly reduced sterol absorption confirmed the fundamental role of this protein as a cholesterol transporter in human enterocytes. After absorption, free cholesterol and fatty acids are re-esterified in the enterocyte by the action of acyl-coenzyme A:cholesterol acyl-transferase (ACAT), packaged with triglycerides, phospholipids and apolipoprotein B-48 into chylomicrons, and finally secreted from the basolateral site of the enterocytes from where they enter the lymphatic channels and eventually are transported into the peripheral circulation ([@b56]). Recent studies have significantly advanced our understanding of intestinal sterol absorption at the molecular level. Two nuclear hormone receptors are believed to be involved in the regulation of cholesterol homeostasis, the liver X receptor (LXR) and the farnesoid X receptor (FXR). The natural ligands for LXR and FXR are oxysterols (oxidized derivatives of cholesterol) and bile acids, respectively ([@b47]).

To modulate transcriptional activity, ligand-activated LXR or FXR form a heterodimer with one additional nuclear hormone receptor, the retinoid X receptor (RXR). These heterodimers control the transcription of several important genes that participate into cholesterol metabolism, sometimes appearing to antagonize the effects of each other. Two mechanism are involved in the reduction of cholesterol following FXR-RXR and LXR-RXR activation ([@b46], [@b45]). The FXR-RXR heterodimer suppresses CYP7A1 expression and decreases bile acid synthesis. Because non-polar lipids such as cholesterol have a limited solubility in the aqueous environment of the intestinal lumen, bile acids are required to solubilize these non-polar compounds and allow their absorption. By suppressing bile acid production, the activated FXR-RXR heterodimer decreases the solubilization and absorption of dietary cholesterol. Even though activation of the LXR-RXR heterodimer could not counterbalance the FXR-RXR-mediated suppression of CYP7A1 expression, the activated LXR-RXR heterodimer has a powerful effect on cholesterol homeostasis by inducing the expression of ABC transporters (specifically, ABCA1) in enterocytes. This increase in ABCA1 expression represents the second mechanism by which the administration of the RXR ligand decreases cholesterol absorption. ABCA1 normally pumps cholesterol from enterocytes back out to the intestinal lumen, thereby limiting the amount of cholesterol absorbed ([@b46]; [@b8]). Indeed, mice treated with the RXR ligand present an increased intestinal expression of ABCA1, mediated by the activation of the LXR-RXR heterodimer. Given these findings, pharmacological activation of the nuclear hormone receptors RXR, LXR and FXR, including PPARs agonist that have been shown to positively affect LXR expression and activity, may represent a treatment option for hypercholesterolemia.

Mechanism of action of ezetimibe
================================

In the past few years, an innovative approach to cholesterol-lowering therapy has been introduced. Ezetimibe is the first in a class of cholesterol-lowering agents with a mechanism of action that is very different from other lipid lowering therapies, including bile acid sequestrants.

By inhibiting cholesterol absorption at the level of the brush border of the intestine, ezetimibe reduces the amount of lipoprotein cholesterol circulated to the liver. In response to reduced cholesterol delivery, the liver reacts by upregulating LDL-C receptors, which in turn leads to increased clearance of cholesterol from the blood ([@b34]).

A major advance in the understanding of ezetimibe's mechanism of action occurred in 2004 when Altmann and colleagues evaluated sequence data from human, rat, and mouse gastrointestinal cDNA libraries to identify proteins with features, such as transmembrane domains and known cholesterol sensing motifs, that would be expected to be seen in a putative cholesterol transporter ([@b1]).

Interestingly, ezetimibe has also been shown to block the uptake of oxidized LDL by human macrophages through inhibition of both NPC1L1 and ANX2/CAV1 ([@b49]; [@b37]), suggesting the actions of this agent may extend beyond the intestinal epithelium. Aminopeptidase N (CD13) in the brush border membrane may represent an additional molecular target for ezetimibe. Ezetimibe has been shown to bind to aminopeptidase N thereby blocking the endocytosis of cholesterol from micelles in the intestinal lumen ([@b37]). Additional evidence has come from in vitro binding assays that tested directly the interaction between the drug and NPC1L1. Garcia-Calvo, with Davis, Thornbury, and colleagues ([@b26]) developed a binding assay and showed that labeled ezetimibe glucuronide bound specifically to a single site in intestinal epithelial brush border membranes and in embryonic kidney cells engineered to express NPC1L1. Furthermore, the binding affinities of ezetimibe and its analogs to recombinant NPC1L1 were indistinguishable from those observed for native enterocyte membranes. Values for the dissociation constant of ezetimibe glucuronide for NPC1L1 were evaluated in intestinal enterocyte membranes and human embryonic kidney cells engineered to express NPC1L1 from various species. Binding affinities were highest for rhesus monkey compared with more moderate values for rat and human, with the lowest values reported for mouse, which also correlates well with the in vivo potency observed for ezetimibe across species. Also, ezetimibe failed to affect cholesterol absorbtion in *Npc1L1*-/- null mice compared with wild-type mice ([Figure 2](#fig2){ref-type="fig"}). These results established NPC1L1 as the target for the action of ezetimibe.
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Ezetimibe is rapidly metabolized in the intestine to its phenolic glucuronide; once glucuronidated, it is excreted in the bile, thereby delivering the drug back to the main site of action. Cholesterol absorption studies indicated that the glucuronide appeared more potent than ezetimibe itself, and this is likely because glucuronidated ezetimibe localizes more avidly to the intestine. Autoradiographic analysis demonstrated that drug-related material was located throughout the intestinal villi but concentrated in the villus tip. In humans, ezetimibe is rapidly absorbed and primarily metabolized in the small intestine and liver to its glucuronide, with little oxidative cytocrome P450 mediated metabolism ([@b43]). Ezetimibe and its glucuronide undergo enterohepatic recycling and have a half-life of approximately 24 hours in humans. Ezetimibe and/or the glucuronide metabolite are excreted in the feces (90%) and urine (10%). Since ezetimibe does not influence the activities of cytocrome P450 enzymes, significant pharmacokinetic interactions with many medications have not been noted. Pharmacokinetic interaction studies of ezetimibe in humans have found no significant changes in the plasma levels of other medications including statins( atorvastatin, simvastatin, pravastatin, lovastatin, and fluvastatin), fibrates (gemfibrozil and fenofibrate), digoxin, glipizide, warfarin and oral contraceptives (ethinyl estradiol and levonorgestrel ([@b33]).

Treating two sources of cholesterol: co-administering ezetimibe together with a statin
======================================================================================

Statins (eg, fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, and rosuvastatin) deliver only single inhibition of cholesterol production in the liver by blocking HMG-Co A reductase, the rate-limiting step in cholesterol synthesis, but do not impact significantly intestinal cholesterol absorption ([@b51]). As a result, hepatocytes become depleted of cholesterol and respond by increasing LDL-C clearance from the blood (via upregulation of hepatic LDL-C receptors) and decreasing entry of LDL-C into the circulation. These actions, in turn, result in the lowering of plasma LDL-C levels. Of note HMGCoA reductase inhibitors could target also cholesterol synthesis in the ileum ([@b42]; [@b54]); therefore reduced cholesterol biosynthesis in the small intestine by statins may also contribute to the reduction of plasma cholesterol concentrations.

The use of two lipid-lowering compounds (ezetimibe co-administered with a statin) with complementary mechanisms of action provides a powerful new approach to prevent and treat atherosclerosis. Treating two sources of cholesterol (rather than one source with statins or ezetimibe alone) results in a substantially greater overall LDL-C lowering efficacy as well as in more patients attaining or getting below LDL-C goals.

Ezetimibe added to a statin has the potential to lower cholesterol by dual inhibition of both cholesterol absorption and cholesterol synthesis. Adding ezetimibe to ongoing statin therapy led to a substantial additional reduction in LDL cholesterol levels, facilitating attainment of NCEP goals. In patients with hypercholesterolemia not at goal on statin therapy alone, the Ezetimibe Add-On to Statin for Effectiveness (EASE) trial ([@b44]; [@b16]) demonstrated that co-administering ezetimibe (10 mg) with any dose of statin reduced LDL-C levels by an additional 25%, compared with the usual 6% attained by doubling the statin dose and improved LDL-C goal attainment from 20% on statin monotherapy to 71% vs 18.9% on statin alone, p \< 0.001 ([@b25]) ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

![Ezetimibe Add-On to Statin for Effectiveness study: percentage changes in LDL-C overall and by NCEP CHD risk category(n = 3030). Drawn from data of Pearson et al(2005).](vhrm0402-267-03){#fig3}

![Ezetimibe Add-On to Statin for Effectiveness study: LDL-C goal attainment for patients (n = 3030) not at goal at baseline. Drawn from data of Pearson et al(2005).](vhrm0402-267-04){#fig4}

The benefits were consistent across the statin brand and dose subgroups, in particular association of ezetimibe with atorvastatin (10--80 mg), fluvastatin (20--80 mg), lovastatin (20--80 mg), pravastatin (10--80 mg), simvastatin (10--80 mg) was studied ([@b16]).

Ezetimibe when co-administered with a statin was significantly better than placebo in increasing high-density lipoprotein cholesterol (HDL-C) and reducing triglycerides, non-HDL-C, and apolipoprotein B (p \< 0.001 for all between-treatment differences). The superior reduction in LDL-C with ezetimibe compared with placebo was consistent across all ages, in men and women, and all ethnicities. Patients with diabetes or metabolic syndrome (including those with or without diabetes) who were randomized to ezetimibe had superior reduction in LDL-C compared with placebo. The superior LDL-C reduction with ezetimibe was consistent when analyzed by statin brand and statin dose.

Other lipid parameters statistically improved with the addition of ezetimibe were: ratios of LDL-C/HDL-C, of total cholesterol/HDL-C and non-HDL-C. Finally C-reactive protein, a non-specific inflammatory marker associated with cardiovascular risk, was further reduced by 12%.

Many studies have centered on the use of ezetimibe/simvastatin as a single tablet: the association was superior to atorvastatin alone in reducing plasma LDL-C at every dose comparison studied, according to double-blind, randomized, forced-titration study ([@b6]). Adult patients with hypercholesterolemia experienced significantly greater reductions in LDL-C when they received the typical starting dose of ezetimibe/simvastatin 10/20 mg (50%) compared with atorvastatin 10 mg (37%) after 6 weeks of treatment (p \< 0.001). Interestingly, the reduction in LDL-C levels seen with the association was comparable to the 50% reduction in LDL-C levels that has shown to be required for reversal of IVUS-evidenced atherosclerosis ([@b44]). In addition, ezetimibe/simvastatin resulted in significantly more patients achieving LDL-C goal (\<100 mg/dL) whether compared with atorvastatin or simvastatin alone ([@b21]; [@b4]) ([Figure 5](#fig5){ref-type="fig"}).

![Vytorin Versus Atorvastatin Study: Achievement of LDL-C \<100 mg/dL in patients with CHD risk equivalent. Drawn from data of [@b4].](vhrm0402-267-05){#fig5}

Further, compared with patients receiving atorvastatin alone, more patients treated with ezetimibe/simvastatin reached the more aggressive LDL-C target (\<70 mg/dL), as recently recommended by the NCEP for very high-risk CHD patients ([@b4]) ([Figure 6](#fig6){ref-type="fig"}). Approximately 23% of patients receiving atorvastatin 40 mg alone and 36% of patients receiving atorvastatin 80 mg alone reached the optional LDL-C treatment target of \<70 mg/dL compared with 57% of patients treated with ezetimibe/simvastatin (10/40 mg) and 64% of patients receiving ezetimibe/simvastatin (10/80 mg) ([@b4]).

![Vytorin Versus Atorvastatin Study: Achievement of LDL-C \<70 mg/dL in patients with CHD risk equivalent. Drawn from data of [@b4].](vhrm0402-267-06){#fig6}

The treatment with the usual starting doses of ezetimibe/simvastatin 10/20 mg resulted in a 51% reduction of LDL-C compared to 36% reduction of LDL-C with the starting dose of atorvastatin 10 mg ([Figure 7](#fig7){ref-type="fig"}).

![Vytorin Versus Atorvastatin Study: LDL-C reductions. Drawn from data of [@b4].](vhrm0402-267-07){#fig7}

Similar data were observed in patients treated with ezetimibe/simvastatin compared to rosuvastatin ([@b11]); patients receiving ezetimibe/simvastatin had statistically significantly greater reductions in lowering LDL-C at all doses and across doses (52%--61%) compared with a potent statin monotherapy agent, rosuvastatin, (46%--57%; p \< 0.001) at the usual starting, next highest, and maximum doses ([Figure 8](#fig8){ref-type="fig"}).

![LDL-C reduction across the dose range. Drawn from data of [@b11].](vhrm0402-267-08){#fig8}

Significantly higher percentages of patients achieved LDL-C levels of \<100 mg/dL (2.6 mmol/L) with ezetimibe/simvastatin versus rosuvastatin.

Furthermore, the greater LDL-C reducing efficacy produced by ezetimibe/simvastatin generally resulted in a higher percent of LDL-C goal attainment, particularly for those high-risk patients who attained LDL-C levels \<70 mg/dL (\<1.8 mmol/L). Patients treated with ezetimibe/simvastatin versus rosuvastatin showed significantly greater improvements in TC, apo B, non-HDL-C, and LDL-C:HDL-C and TC:HDL-C ratios at all dose comparisons, and also in TG at the usual starting doses (10/20 mg versus 10 mg), the maximum doses (10/80 mg versus 40 mg), and when averaged across all doses. Improvements in HDL-C and hsCRP were similar for both study medications at all dose comparisons. The EXPLORER study evaluated whether the association of rosuvastatin 40 mg with ezetimibe 10 mg enables more high-risk patients to achieve the LDL target compared with rosuvastatin monotherapy. This study demonstrated that the addition of ezetimibe increased goal achievement to 94% with 70% mean reduction in LDL-C ([@b5]). Similar results were obtained in another small study, in severe hyperlipidemic patients, resistant to 40 mg rosuvastatin monotherapy. LDL-C levels were reduced by 51% with the association rosuvastatin 40 mg/ezetimibe 10 mg, 45% of the patients achieved LDL-C values below 100 mg/dL ([@b36]). The VYTAL study compared the efficacy and safety of the recommended usual starting and next highest doses of ezetimibe/simvastatin and atorvastatin in patients with diabetes mellitus and hypercholesterolemia ([@b28]). The association of ezetimibe/simvastatin provided significantly greater mean reduction in LDL-cholesterol levels 10/20 mg (−54%) vs atorvastatin 10 mg (−38%, p \< 0.001) or 20 mg (−45%, p \< 0.001) and with ezetimibe 10/40 mg (−58%) vs atorvastatin 40 mg (−51%, p \< 0.001). Ezetimibe/simvastatin was also superior to atorvastatin in attainment of LDL-cholesterol levels less than 70 mg/dL (p \< 0.001 for all doses comparisons).

When administered in monotherapy, ezetimibe 10 mg/die showed a similar adverse events (AE) profiles compared to placebo ([@b19]). Most of the adverse events (AEs) were judged by the investigators to be mild or moderate at their greatest intensity. Overall a similar percentage of patients reported AEs in ezetimibe group then in the placebo group (63% vs 66%). The nature, number and pattern of occurencies of AEs that led to study discontinuation suggested no differential risk with ezetimibe treatment related to placebo; 3% of placebo and 4% of ezetimibe recipients discontinued due to AEs. Laboratory test results were generally similar between treatment groups. The incidence of elevated laboratory function test values (ALT and/or AST \> 3x the upper limit of normal (ULN) at two consecutive visits \>1 week apart) was \<1% in both placebo and ezetimibe treatment groups. Elevated muscle enzyme values (CK \> 10x ULN) were reported in less than 1% of groups. All the observed increases were asymptomatic and either transient with continued treatment or reversible following treatment discontinuation.

When associated with statins, approximately 95% of patients completed the treatment ([@b25]). Gastrointestinal system disorder was the most common AE leading to discontinuation, occurring in 1% of patients. In phase II and III studies of the statin plus ezetimibe group, 20% of patients had what the investigator considered to be treatment-related AE compared to 17% in the group of patients receiving statin and placebo (10% of AE incidence was related to gastrointestinal system disorders). Elevation in either ALT or AST \> 3x ULN at two consecutive pos-line measurements were similar in the two treatment groups(1% and \<1% respectively). No case of rhabdomyolysis was reported in ether treatment group.

In the EASE study ezetimibe add-on to statin was well tolerated with a safety profile comparable with placebo ([@b16]). When adverse events were evaluated for each of statin groups (simvastatin, atorvastatin, and other), no particular pattern was found among patients receiving ezetimibe versus placebo for any adverse event category ([@b25]). Results of additional measurements of safety revealed no evidence of any adverse effects of ezetimibe treatment compared with placebo relative to statin monotherapy. In general, there were no significant differences between ezetimibe/simvastatin and rosuvastatin ([@b11]) in terms of clinically significant elevations in levels of muscle or liver enzymes. With regard to the liver enzymes ALT and AST, ezetimibe/simvastatin tended towards a numerically higher frequency of elevated levels, compared with rosuvastatin, partially attributed to differences at the 10/80 mg and 40 mg doses, but not at lower doses. Both study drugs were generally well tolerated. In conclusion, while the combination of ezetimibe with moderate doses of statins appears to be reasonably safe, the long-term safety of combination with high doses of statins remains to be established ([@b14]). More data are expected from the ongoing trials described below.

Ezetimibe, dyslipidemia and cardiovascular outcomes: future developments
========================================================================

Although treating two sources of cholesterol through dual inhibition provides superior LDL-C lowering efficacy with improved LDL-C goal attainment, one key clinical question remains to be addressed: Do the lower LDL-C levels achieved with dual inhibition of cholesterol production and absorption ultimately translate into reduced cardiovascular or renal events and a slower rate of progression of atherosclerosis? This question is currently being assessed in several major cardiovascular outcomes studies, including Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE), Improved Reduction of Outcomes: Vytorin™ Efficacy International Trial (IMPROVE IT), Simvastatin and Ezetimibe in Aortic Stenosis Study (SEAS), and Study of Heart and Renal Protection (SHARP). These major endpoint trials collectively involve more than 21,000 patients.

More recently ezetimibe has been co-administered with fenofibrate in patients with mixed hyperlipidemia ([@b39]). Preliminary results after completing the 12-week randomized double-blind base study showed that the association of ezetimibe to fenofibrate produced significantly greater reduction in LDL-C (−22% vs −9% respectively; p \< 0.001). There were also significantly improvements in TG, HDL, total cholesterol and non-HDL-C with fenofibrate + ezetimibe compared with fenofibrate alone. Overall fenofibrate plus ezetimibe was well tolerated and the proportion of patients with consecutive elevations of ALT or AST \> 3x the normal limit was similar (1.2% fenofibrate + ezetmibe vs 1.7% fenobibrate alone). The efficacy of the association of ezetimibe/simvastatin 10/20 mg with fenofibrate 160 mg has been investigated in patients with mixed hyperlipidemia ([@b20]). LDL-C was significantly reduced with eze/simva + feno (−45.8%) compared with feno (−15.7%) or placebo ( −3.5%). Treatment with eze/simva + feno was generally well tolerated with a safety profile similar to the eze/simva and feno therapies. Further studies are warranted to investigate the role of ezetimibe and fibrates in mixed dyslipidemia.

Conclusions
===========

A wide therapeutic gap exists between target LDL-C levels and LDL-C levels typically achieved in actual clinical practice -- a gap that will certainly widen with traditional therapy of single inhibition in light of recent amendments to the NCEP ATP III guidelines. The new aggressive cholesterol treatment goals call for a more advanced therapeutic approach to maximize the cardiovascular benefits associated with lower LDL-C levels. One logical approach is to target both cholesterol production in the liver and absorption in the intestine. By administrating ezetimibe/simvastatin as a single tablet or co-administering ezetimibe together with any dose of any statin, we can expect superior LDL-C-lowering efficacy and a substantially greater proportion of patients achieving or getting below LDL-C treatment goals. Treating two sources of cholesterol through dual inhibition should therefore be considered as a more advanced therapeutic option for all hypercholesterolemic patients whose LDL-C levels are not appropriately controlled approximately 2-3 months after initiating statin monotherapy.
